Mark C. Dessing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mark C. Dessing has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Loes Butter
Department of Pathology, Amsterdam UMC (location AMC), University of Amsterdam
2 shared publications - Sandrine Florquin
Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
2 shared publications - Ann Marie Schmidt
Diabetes Research Program, Department of Medicine, New York University Grossman School of Medicine, New York, USA
1 shared publication - Coert J. Zuurbier
L.E.I.C.A., Department of Anesthesiology, Amsterdam UMC, Cardiovascular Sciences, University of Amsterdam, Amsterdam, The Netherlands
1 shared publication - Elena Rampanelli
Department of Experimental Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands
1 shared publication G. J. Teske
Pathology, Academic Medical Center, Amsterdam/NETHERLANDS
1 shared publication
Latest Publications
- Open Access
- 16 June 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (8) , 2405-2420
NLRX1 dampens oxidative stress and apoptosis in tissue injury via control of mitochondrial activity
Mitochondrial dysfunction is the most prominent source of oxidative stress in acute and chronic kidney disease. NLRX1 is a receptor of the innate immune system that is ubiquitously expressed and localized in mitochondria. We investigated whether NLRX1 may act at the interface of metabolism and innate immunity in a model of oxidative stress. Using a chimeric mouse model for renal ischemia-reperfusion injury, we found that NLRX1 protects against mortality, mitochondrial damage, and epithelial cell apoptosis in an oxidative stress–dependent fashion. We found that NLRX1 regulates oxidative phosphorylation and cell integrity, whereas loss of NLRX1 results in increased oxygen consumption, oxidative stress, and subsequently apoptosis in epithelial cells during ischemia-reperfusion injury. In line, we found that NLRX1 expression in human kidneys decreased during acute renal ischemic injury and acute cellular rejection. Although first implicated in immune regulation, we propose that NLRX1 function extends to the control of mitochondrial activity and prevention of oxidative stress and apoptosis in tissue injury.
- 16 June 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (8) , 2405-2420
Open AccessNLRX1 dampens oxidative stress and apoptosis in tissue injury via control of mitochondrial activity
Mitochondrial dysfunction is the most prominent source of oxidative stress in acute and chronic kidney disease. NLRX1 is a receptor of the innate immune system that is ubiquitously expressed and localized in mitochondria. We investigated whether NLRX1 may act at the interface of metabolism and innate immunity in a model of oxidative stress. Using a chimeric mouse model for renal ischemia-reperfusion injury, we found that NLRX1 protects against mortality, mitochondrial damage, and epithelial cell apoptosis in an oxidative stress–dependent fashion. We found that NLRX1 regulates oxidative phosphorylation and cell integrity, whereas loss of NLRX1 results in increased oxygen consumption, oxidative stress, and subsequently apoptosis in epithelial cells during ischemia-reperfusion injury. In line, we found that NLRX1 expression in human kidneys decreased during acute renal ischemic injury and acute cellular rejection. Although first implicated in immune regulation, we propose that NLRX1 function extends to the control of mitochondrial activity and prevention of oxidative stress and apoptosis in tissue injury.
- Open Access
- 1 July 2010
- Published by Wolters Kluwer Health in Transplantation
- Vol. 90, 472
ANTI-HMGB1 BUT NOT SOLUBLE RAGE AS THERAPEUTIC INTERVENTION IN EXPERIMENTAL RENAL ISCHEMIA/REPERFUSION-INDUCED INJURY
- 1 July 2010
- Published by Wolters Kluwer Health in Transplantation
- Vol. 90, 472
Open AccessANTI-HMGB1 BUT NOT SOLUBLE RAGE AS THERAPEUTIC INTERVENTION IN EXPERIMENTAL RENAL ISCHEMIA/REPERFUSION-INDUCED INJURY